What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Surgery, Oncology, Gemcitabine and Cancer.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
His Surgery research incorporates elements of Clinical trial and Oxaliplatin.
The Oncology study combines topics in areas such as Pharmacokinetics, Chemotherapy, Sorafenib, Epidermal growth factor receptor and Adenocarcinoma.
His Gemcitabine research is multidisciplinary, relying on both Clinical endpoint and Pancreatic disease.
His Cancer research is multidisciplinary, incorporating perspectives in Psychiatry and Mediation.
His most cited work include:
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. (4625 citations)
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine (3192 citations)
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (3088 citations)
What are the main themes of his work throughout his whole career to date?
Malcolm J. Moore spends much of his time researching Internal medicine, Oncology, Surgery, Chemotherapy and Gemcitabine.
The study of Internal medicine is intertwined with the study of Gastroenterology in a number of ways.
His biological study spans a wide range of topics, including Cetuximab, Clinical endpoint, Randomized controlled trial and Phases of clinical research.
In his study, which falls under the umbrella issue of Chemotherapy, Pharmacokinetics is strongly linked to Toxicity.
The concepts of his Gemcitabine study are interwoven with issues in Pancreas, Oxaliplatin, Erlotinib and Cisplatin.
His Colorectal cancer research includes themes of Bevacizumab, Adjuvant therapy and Hazard ratio.
He most often published in these fields:
- Internal medicine (72.44%)
- Oncology (53.85%)
- Surgery (33.97%)
What were the highlights of his more recent work (between 2012-2020)?
- Internal medicine (72.44%)
- Oncology (53.85%)
- Pancreatic cancer (22.44%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Surgery.
His study on Cancer, Colorectal cancer, Chemotherapy and Adverse effect is often connected to In patient as part of broader study in Internal medicine.
The Oncology study combines topics in areas such as Cancer centre, KRAS, Proportional hazards model and Pancreas.
His Pancreatic cancer study incorporates themes from Clinical trial, FOLFIRINOX, Mortality rate, Confidence interval and Adenocarcinoma.
The concepts of his Gemcitabine study are interwoven with issues in Gastroenterology, Oxaliplatin, Erlotinib and Phases of clinical research.
His research investigates the connection with Surgery and areas like Radiology which intersect with concerns in Lymph node, Retroperitoneal lymph node dissection and Lymph.
Between 2012 and 2020, his most popular works were:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine (3192 citations)
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (857 citations)
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial (857 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Malcolm J. Moore focuses on Internal medicine, Oncology, Pancreatic cancer, Gemcitabine and Gastroenterology.
Hazard ratio, Proportional hazards model, Cancer, Paclitaxel and Clinical trial are the primary areas of interest in his Internal medicine study.
His Oncology study combines topics from a wide range of disciplines, such as Cetuximab, Colorectal cancer, Nab-paclitaxel and Pancreas.
His Pancreatic cancer study integrates concerns from other disciplines, such as Chemotherapy, Retrospective cohort study, DNA mismatch repair, Confidence interval and Veliparib.
His Gemcitabine study results in a more complete grasp of Surgery.
His Gastroenterology research is multidisciplinary, incorporating elements of Pharmacokinetics and Deoxycytidine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
